Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
delusional investors won't accept reality.
The bankruptcy force to sell all assets of any value to Taran Theureuptic who now own the patents.
What don't you understand? People keep talking about short squeeze and LENZ etc talking non-sense
Lawsuits are waste courts' time
Two judges had to waste time hearing two fake court hearings.
The company has less employees than a 7-11 convenient store. and in the financial statements its assets are worthless.
The shares are more like an option with an expiry date than shares or equity as of today.
That is the reality of the ticker but people who thought they were investing some molecule still wont accept the reality their investment is worth 99,999% less than
they paid for it. if you bought the shares at .15/share and think the shares would be worth at least a buck, well as of now there is no chance it will ever be worth $1 without FDA approval since LENZ doesn't own the LENZ patent even LENZ is approved it will never be worth $5 again.
the company only has only 3 full time employees, that is how small this company is.
And management of this company is not investable too. management is a liability in this company.
Companies like humanigen don't have any positive cashflow from business operations. it's like charity, all expenses is funded by shareholders injecting cash into to fund research and the CEO $400,000/year salary. The business has no revenues. only source of cash or revenue was investors who bought the shares, and that initial cash has dried up and due to the $3 million lawsuit and $1 million in legal fees, there is no cash left. and reason for the bankruptcy, Investors see lawsuits a debt. that 40 million liability is same as bank loan debt. and reason nobody will invest in shares of the company with that much debt or liability. and on the book the IP assets are 'worthless' so why invest.
The company managmenet deliberattely choos to not file SEC reports and get delisted. and be at the expert market. I've seen bankrupt companies have qoutes. as long as the company file SEC reports. The company has not filed any quarterly reports, which is the minimum to get listed in any exchange. it doesn't matter if company is bankrupty, have no assets, no employees. when trading in the pinksheets unlike nasdaq and NYSE listings. To be listed in the nasdaq, you need assets to be min. $100 million. in your balance sheet and share price min. of $1.. OTC markets there is no listing requirments other than filing the quarterly SEC reports. even if you have no financial statements. They just to know the company exist.
There is no reason the OTC markets not public level 2 or not quotes. the stock can get delisted too if company doesn't file SEC reports.
The stock is now tradinng at the OTC or pinksheet which is less regulated that a flea market or craigslist. and facebook marketplace
look at the data. If the exchange can b.s. like this with fake documents saying the short position and authorized shares is 250 million shares. outsanding shares is 119 million shares. who are these idiots talking about recalling 125 million shares is that a naked short. Did some market maker short 250 million shares. Naked shorting can only be done by broker dealers market makers, it's a privillege only professionals can get. like citadel not retail accounts.
The One guy who owns the company controls over 90% of the trading shares and is also the market maker. in the otc it shows 38,000 shares still short at .0001 anyone still short is a market maker or broker dealer. no retail would short a stock or still holding a short position when stock is .00001 for months. so the expert market is b.s. too. like this market.
The company is now shell company with no liabilities, no assets, and no employees. What don't you dreamers don't understand. As for the shareholders, you are not shareholders since management would not even answer your phone calls, You own the stock ticker on the portfolio but you don't own the company. You have no say on management decisions.
HGENQ doesn't own the patents to LENZ anymore, it's sold it for nothing.
Creditors get nothing. nor does the any of the claimants who think they should get .047/shares. with the $3 million dollar payout settlement that was agreed to pay before the chapter 11 filing. The company doesn't have $3 million to pay and if does pay, the law firm would deny claims or not pay as HGENQ if paying is paying to the law firm who filed the lawsuit not to individual investors who think they were entitled to anything and paid $500 or something to application fee for the payment. Probaably wasted your time scanning documents an sending your information to the law company asking for proof you bought the shares between may 16 2020 and july 13 2022. You know how hard to confirm you bought it? It impossible or very time consuming to verify who bought it between may 16 2020 and july 13 2022. That can only be confirmed by broker electronically, paper can be fake documents showing your bought it.
If you're not a shareholder, please go away from here and take your time.
I agree with both of you. .....and I have lost more here than 90% of anyone who has ever posted on this board. I don't need this "newbie" to describe anything to me. I also question purpose of said posts.
I don’t get it either, this person has been doing it several times with several various screen names here and another message board.
Not going to argue the validity of his posting, just seems a strange way of doing it?
First, thank you for your information. but why go to the extent of creating an account just to refute in such detail? Is it a sense of public duty?
the $3 million dollar settlment doesn't make logical sense either. the shareholders bought shares between $20 to $4 were to get .047/share as a settlement. its peanuts if they loss $100,000 with 20,000 shares and average cost was $5 but only get $940 settlement after pay legal fees they get $500?
and they sold. their shares too. How the legal settlement got $3 million value is the question.
Only the broker can verify and confirm that a particular shareholder bought shares from may 16- july 2022. and it cost money to confirm that. How can they confirm any claim that the paper documents are real and not fake? The easiest way was via the transfer agent who has all the records and no need to ask people to send in claims for payment . The brokers charges $300 to remove a delisted stock from your portfolio and only takes a few minutes to do. The transfer agent has all the info or shareholder list in a particular time period. you had to be buyer of the shares to qualify. and that is another problem to pay. if you bought less than $100 worth of shares, it cost more to print a check and send it to your home address. The transfer agent has no record of who bought the shares they just have record of who owned the shares so this $3 settlement is rediculous saying only people who bought the shares are entiteled and max is only $3 million they can pay out
The 3 million dollar settlement is void and discharged after chapter 11 isn't it. and is bogus lawsuit who claim to have loss money due to management mislead. There were way more shareholder losses than 3 million. More likely the firm gets the 3 million but don't pay a dime to the claimants because who can the confirm people sending the proofs were real shareholders who bough the shares from may 16 2020- july 12 2022. For legal business you are saying only people who bought the shares on that date is qualified? This is wall street, shareholders are taking the risk and know the risk, very few companies pay their shareholders for this kind of lawsuit, it's like shareholder suing the company for compensation, but the company has no money to pay and goes bankrupt, shareholders loses on his investment and gets no payment.
Yesterday, was the last day or March 20, that any creditors can object to the discharge, no creditor objected so all their claims or the 40 million is no void and invalid. The gov't has or any gov't has til july 1 to object to the chapter 11 as that is highly unlikely any gov't would waste any more time in this chapter 11 filing. Essentially, the companies has no liabilities. and no assets. other than claim like an option on Taran who bought the assets. Taran didn't even have to pay anything or agreed to the schmuck insurance. As for the .047/share payment with the $3 million dollar settlement, that was before the chapter 11 filing. How anyone can prove they bought owned the shares is questionable as that information is only available in the brokers records. The law firm who filed the lawsuit if they do get any payment from HGENQ can just keep the $3 million.
After chapter 11 HGENQ is now a shell company with no assets, no liabilities, and no employees.
LENZ and all intellectual property was sold for nothing
Any talk of 'recalling' shorted shares is non-sense. and delusional as all the shorts covered their short positions. Either your doing a pump and dump scheme in a shell company, why even talk about 'short squeeze'. There is no short squeeze.
Now if the shares were to got o. 35/share it won't be short squeeze or even pump and dump, it would be cause FDA approves LENZ for manufacturing and commercialization. The licensing few is only a few millions. and that is payable to Taran who now owns the IP for LENZ or any biotech patent that humanigen had.
so are you claiming that july is the last incoming and then they can reverse after that?
regardless of whether or not they can do that why would anyone be perilously short with the history of this company. surely nobody could discount what they might try.
on another note since taran is private, lets say they get a voucher for x dollars. ( i doubt it)
do they have to report it or would it be reported by default?
jay if you are correct and lenzilumab has all this unbelievable potential , what makes you think the market didn’t realize it long ago like you
Please take further notice that on March 19, 2024, the Court entered an order (the “Bar Date
Order”)2
establishing: (i) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “General
Bar Date”) as the last date and time for each person or entity to file a Proof of Claim in this
Chapter 11 Case, including claims arising under section 503(b)(9) of the Bankruptcy Code;
(ii) April 22, 2024 at 5:00 p.m. (prevailing Eastern Time) (the “Administrative Claims Bar
Date”) as the deadline for each person or entity that asserts a request for payment of administrative
expense claims (collectively, the “Administrative Claims”) arising between the Petition Date and
February 20, 2024 (the “Administrative Claims Deadline”) to file a request for payment of such
Administrative Claims; and (iii) and July 1, 2024 at 5:00 p.m. (prevailing Eastern Time)
(the “Governmental Bar Date”) as the date by which all governmental units holding claims
(whether secured, unsecured priority, or unsecured non-priority) that arose (or are deemed to have
arisen) before the Petition Date must file Proofs of Claim, including claims for unpaid taxes,
whether such claims arose from prepetition tax periods or prepetition transactions to the Debtor
were a party https://document.epiq11.com/document/getdocumentbycode?docId=4309765&projectCode=HUM&source=DM
If they would have recalled the shares before BK, they would have had to pay back the 40 million they owed. The share call back is speculative but what I don;t understand is why not declare liquidation? Why keep the share structure in place
You could be absolutely right, dlog.
Because I believe in the huge potential of lenz to effectively treat, and then to possibly prevent, a huge number of indications, and also because I believe in the good character of our management, I have made it my objective to try to understand what this management team is doing to get their lenz into the market. And I have shared my conclusions and opinions here.
Yes, there would have been benefit with an earlier recall of the loaned shares. It would have amounted to a blip on the radar. Even if it staved off the bankruptcy, the momentum would not have been sustained, without news leading to our ability to generate a revenue stream.
In the US, and in the UK, we're looking for regulatory approval for lenz to treat covid. That would cause the FDA and the MHRA to destroy the markets for Pfizer and Moderna, who provide the vast majority of the regulators' operating funds. It would also threaten the value of the intellectual property OWNED BY THE REGULATORS in the Pfizer and Moderna mRNA vaccines. Regulators would be slicing their own financial throats by approving Humanigen's lenzilumab, and the Novavax vaccine that uses lenz as an enhancement.
We have to capitalize on the IND authorization by having partners use lenz under IND for their vaccine and CAR-T products. We also need to exploit our opportunity for regulatory approval of lenz from Australia, to treat CMML. It's almost "game-over" for the attempts to deny our revenue stream. We will prevail. It would be an absolute catastrophe to use mRNA technology to fight a virus that could have 100% mortality, such as the Pangolin Coronavirus.
We need to see regulatory approval of lenz, which is most likely to first come from Australia. And the flood gates will then be open.
And that's when management can recall their loaned shares to the fullest monetary advantage.
seems to me if what you believe is true, the “share recall” could have solved all the company problems.
there would have been no need for any BK
its just more fantasy just like novavax is a fantasy.
Are you insane?
there are no shares to recall here
what martee did do with kalobios pissed off the bowel of wall street . he secretly purchased the float , then stopped loaning shares which caught these nice folk with pants down .
he did what is pretty much forbidden on wall street . he ripped off the crooks.
that action only added to his pariah image.
fast forward to Cam- he would NEVER TRY TO PULL THAT KIND OF STUNT. even if he could. he bows to the street
jay talks arcanely about the special share structure he cant clearly explain, and uses a share number that popped up for a day on this site of all places.
there are no shares to recall here. all the institutional money shorted this to zero to extract as much as they could make back
there are so many ways for pros to grift money out of pennies, and they fight for the proceeds with management, like dale who made a fortune off this scam
the one thing cam talks about post apocalypse has nothing to do with the shareholders he deserted and desecrated .
theres a reason two retail were able to purchase 10% of company for a few thousand bucks. lol
I don't think it had anything to do with calling shares or with kalobios. He was just a crook....so yes he made enemies.
Martin Shkreli, also known as the “Pharma Bro,” is in prison due to his involvement in securities fraud. Here are the key details:
Securities Fraud Charges:
In 2018, Shkreli was found guilty of two counts of securities fraud and one count of securities fraud conspiracy.
His actions defrauded investors in two hedge funds and a former drug company called Retrophin.
Shkreli manipulated information to defraud investors, ultimately leading to significant financial losses.
Price Hike Controversy:
While Shkreli gained infamy for raising the price of a life-saving HIV drug from $13.50 per pill to an exorbitant $750 per pill, his arrest was not directly related to this incident.
Instead, his charges stemmed from fraudulent activities during his time with Retrophin and other financial schemes.
Sentencing and Consequences:
In 2018, Shkreli was sentenced to seven years in prison.
As part of his punishment, he is permanently barred from serving in any capacity in the pharmaceutical industry and from running a public company.
Those .0003's make my account look pretty Green. My average is at .00027.
im glad your optimistic.
i believe this is toast
that barliant guy helped him scam us too with the slick BK
shkreli went to jail with the enemies he made recalling shares lol
there will be no such thing here
I think Shkreli executed the recall of the loaned shares to re-pay his hedge fund clients from the short squeeze proceeds. Regardless of whether I over-estimated his character, or not, our short squeeze proceeds will go to funding our operational requirements, and likely regain compliance with OTC requirements for quotation, before moving back to Nasdaq.
Novavax's financial condition can do a complete reversal, if their prototype vaccine incorporated a lenz enhancement.
Anyway, once the pieces are in place, then will be the time to evaluate what "...cam has shown..."
My tenacity is just a reflection of my conviction in the character of our management, and in the safety and efficacy of lenz, which is poised to be enthusiastically embraced by the medical community, for a whole host of indications. We've never been stronger, but we will be.
You and I both posted here initially in 2015, so your opinion of me is based on a pretty complete awareness of my conclusions. I may have been able to make a more complete case, for instance, in regards to the share recall, perhaps if those records weren't sealed, and if we saw the charges against Dale's entities. The SEC didn't waste any time after the Kalobios squeeze, and charges against Dale's entities go all the way back to the very time that we became Humanigen. Still, I think Dale very likely won his Appeal. The share structure was managed meticulously, and I believe we will see a float of ~229M shares, which will cause a monster short squeeze when the loaned shares are recalled.
You are correct in saying that an opportunity with Novavax exists only in my head. There's been no sign of it otherwise. But they are the prime candidate that would qualify to use our lenz/vaccine patent, and I think they will have that opportunity as the deadly mRNA vaccines are losing market share, even before the Humanigen/Novavax product comes to market.
Hopefully, we have a pretty decent revenue stream from Gracell, and also hopefully we will be able to snag Tera-Immune, especially if Sanofi expands our opportunity to use the Treg process. Sanofi has always had a complimentary product line to Humanigen, and I look forward to the spin-off of their healthcare business. Don't discount that potential. They were here even before we showed up in 2015.
Up to 15 cases of measles in Chicago now. Two different migrant shelters are impacted as well as a case in the schools
Considering that many of the people entering the US illegally are coming from countries that do NOT have vaccination rates better than 70% (Except for China, which is at 99%), that means that at least 30%, OR MORE, of their populations are NOT vaccinated. While you may not like Tucker Carlson, and feel it neceassry to name call those that may wish to watch or listen to his programs, you cannot ignore the very real likelihood that the resurgence of measles in this country can be, in large part, directly attributed to so many unvaccinated people crossing our borders.
"I don't think there is any way in hell that Pfizer and Moderna will stay in the covid vaccine market past the end of the year, and run the risk of putting their mRNA vaccines into the market, without immunity from prosecution."
We'll see if that proves to be the case. It would definitely mean admitting defeat on the course that Pfizer, Moderna, and the FDA have been mandating.
And in the UK, I see what could be further recognition that the wrong covid treatment course was chosen. The UK announced that the fourth module of their national Covid-19 Inquiry will be rescheduled.
start at the beginning. this section of information concludes at the 4 minute mark, and goes on to an important discussion of 'Disease X.'
I believe the price movement has been very weird going back to the trials. Even before BK I never understood why CYDY traded higher than HGEN. HGEN had an actual product. I can guess that extra shares are out there or the stock price has been manipulated but I do not know for sure. Total speculation in trying to piece things together
Do you truly believe that there are not millions of shares in a shorted situation at this time? Doesn't matter who loaned them......they will automatically be called in when a merger happens and the price will skyrocket as the crooks scramble to cover. They are/were taking a calculated chance that bankruptcy would destroy Humanigen and they would NEVER have to cover (giving them free, untaxable money)......NOW????
A reverse merger makes sense if short shares are recalled. Taran becomes a publicly traded company with a lot of cash on hand. But we do not know if any shares were loaned out to recall. It does seem like a long shot, however
I PRAY YOU ARE RIGHT!!! This would be such a Huge Blessing for Me!!!
It's not complicated. A reverse merger makes Taran a public company (able to sell stock to raise money) and it calls all of Humangien's counterfeit and illegal short shares. Sounds very doable to me. Humanigen is now a gold mine for Cameron.... and for us.....all thanks to the shorting crooks who claim they are doing a service for the markets.....while all the time trying to destroy and drive into bankruptcy a small company trying to do a service to humanity.....so that they never have to pay taxes on their ill-gotten gains.
Tell it to the bankruptcy court judge. He obviously saw no cause to convert the case to CH7, which he should have done, if you guys are right about how worthless we are.
But you're right about the reaction we should have gotten from the clinical trials. The reaction we got from the Top Line Data should have indicated what to expect from the FDA decision.
All the assets including inventory and equity in subsidiaries go to Taran . Unless we somehow are enamored with the name there is nothing of value except cash of 2.5 mil less chapter 11 expenses . They need that’s cash to settle any unsettled debts from chapter 11 debts . hope cash there , is enough to give us multiples on the recall of an unknown number of shorted shares . If we are expecting a miracle , it should have happened with the trials . Covid trials had bankrupted the company . To somehow reuse that data and make money is …. I think you need something stronger to smoke .i am a positive person but even I can’t get that high ! Cameron pulled the carpet from right under our feet . Reverse merger ? What is Tarans benefit , unless they want the balance cash from humanigen that they gave . I doubt there will be any left after they give themselves a fat bonus for the APA .
The powers that be are losing control. Patients and doctors are not buying the mRNA vaccines as they were. It's time for lenz.
The $10K was the company's stated price for the therapeutic infusions.
I wondered about the cost of lenz, if used as a vaccine enhancement. Dosage and formulation of lenz for that application may be substantially less.
I would love to see you be proven right, but unfortunately the powers to be want us to get as much mRNA vaccines as possible. It's about getting the nano tech into us:
The vascular surgeon did two atherectomies in a procedure last year, leaving me with a long stent. I was supposed to have a follow-up visit with him last week, which was contingent on how much that was going to cost. The doctor's staff told me last week how much the insurance wouldn't pay, and I rescheduled the appointment. And yes, for the first time in my life, I began taking a few prescription drugs last year, as you surmised.
I hate to leave the house, but I have always hated leaving the house. It's just that this time, I drag my feet getting ready, until I finally succeed in becoming too late to go anywhere.
jay there will be no share recall
pure fantasy
lenz will never treat covid, we have an abundance of chowder heads who like the vaccines
novavax doesn’t even know who taran or humanigen are
how you believe a drug they tried to say was valued at 10k per treatment could ever be used as a vaccine prophylactic is way beyond fantasy , maybe hallucinating
sorry
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43270
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |